President Donald Trump, seemingly stung by Meghan Markle's recent comments about the upcoming US elections, slammed the actress on Wednesday, saying he was "not a fan" and wishing her husband Prince Harry an ironic "good luck."
- PoliticsGood Morning America
As U.S. Judge Amy Coney Barrett’s name has emerged atop a list of possible replacements for the late Justice Ruth Bader Ginsburg on the Supreme Court, her long affiliation with a small, Charismatic Christian community in Indiana has drawn fresh attention – in part due to the group’s historical use of the term “handmaid” to describe its female members. The ecumenical organization, People of Praise, has fought to distance itself from comparisons to the oppressive fictional religious order in the Margaret Atwood book and television adaptation, "The Handmaid’s Tale."
- U.S.NBC News
'Ashamed of this decision': Backlash toward Kentucky AG piles on after no charges are filed in Breonna Taylor's death
"People are not happy at this point. There's a lot of anger and frustration and sadness," a political science professor said.
- LifestyleEat This, Not That!
If you were a kid in America in the '90s, there's a good chance you had a McDonald's Happy Meal at least once in your life. And it was even better if you had a McFlurry or an apple pie to finish off the meal once you were done with your McNuggets.But if you've gone to the Golden Arches recently and noticed that the apple pie just wasn't the same, you aren't imagining things. McDonald's changed its apple pie recipe in 2018 to make the dessert a bit healthier, much to fans' chagrin. (And, really, the McDonald's apple pie still isn't a healthy choice.) Here's what's different about the apple pie from the days you had it in your youth.And for more, don't miss these 15 Classic American Desserts That Deserve a Comeback. The original McDonald's apple pie was deep-friedThe McDonald's apple pie dates back to 1968 when it debuted on the fast-food chain's menu in all its deep-fried glory.The current iteration of the McDonald's apple pie, meanwhile, is baked. It's better for you (although still not good for you), but plenty of fans want the older recipe back.RELATED: Sign up for our newsletter to get daily recipes and food news in your inbox! How is the new apple pie "healthier?"McDonald's current apple pie recipe doesn't feature high fructose corn syrup, and you won't find any preservatives or artificial colors, either. But don't be fooled: The baked apple pie still includes sugar and palm oil among its ingredients, and each serving contains 15 grams of sugar, along with a whopping six grams of saturated fat. You won't find this treat winning any nutrition awards—you'd be better off with our homemade Best-Ever Apple Pie Recipe.And if you just can't get behind the new apple pie recipe, there's a silver lining: McDonald's offers other pies seasonally, like the custard-filled holiday pie and the baked pumpkin pie. Plus, Popeyes offers a crispy, cinnamon-coated apple pie—it won our fast-food pie taste test!RELATED: Your ultimate restaurant and supermarket survival guide is here!Gone are the days of the old apple pie recipe, along with those Happy Meal graham cookies shaped like the McDonaldland cartoon characters. But you can always order these Secret Menu Options at McDonald's if you want to spice up your fast-food order.And for more, check out these 108 most popular sodas ranked by how toxic they are.
- EntertainmentThe Wrap
(Spoiler alert: Do not read this post if you do not want to know who won Season 15 of “America’s Got Talent.” But also, why did you click on it?)“America’s Got Talent” has crowned its Season 15 winner: Congratulations to Brandon Leake!On Wednesday, Alan Silva (aerial act), Archie Williams (singer), BAD Salsa (dance duo), Bello Sisters (hand-balancing act), Leake (spoken word artist), Broken Roots (singers/musicians), Cristina Rae (singer), Daneliya Tuleshova (singer), Kenadi Dodds (singer/musician) and Roberta Battaglia (singer) duked it out for the $1 million grand prize and the opportunity to perform live at Luxor Las Vegas.Also Read: Fox and Its 'Cosmos: Possible Worlds' Premiere Settle for 5th-Place Ratings Tie With TelemundoCONGRATS @Called_To_Move!! WINNER OF AGT Season 15!! pic.twitter.com/TWv5QZb00l— AGT Auditions (@AGTAuditions) September 24, 2020Blake Shelton, Usher, OneRepublic singer Ryan Tedder, Ava Max, Bishop Briggs, JP Saxe and Julia Michaels performed on the Season 15 finale, as did “AGT” Season 14 finalists, the Detroit Youth Choir.YouTube star David Dobrik also dropped by the NBC broadcast to entertain judges Heidi Klum, Howie Mandel, Sofia Vergara and host Terry Crews.Format creator Simon Cowell has been absent from “America’s Got Talent” since breaking his back in August in an electric-bike accident.Also Read: Chris McCumber to Exit as USA Network and Syfy President Amid Next Wave of NBCU Reorg“America’s Got Talent” was created by Cowell and is co-produced by Fremantle and Syco Entertainment. Cowell, Sam Donnelly, Jason Raff, Trish Kinane and Richard Wallace are the executive producers.Auditions for the next season of “America’s Got Talent” are currently underway.Below are the official bios of the 10 “AGT” Season 15 finalists, as provided by NBC.Also Read: Pearlena Igbokwe Sets Leadership Team for Universal Studio GroupAlan Silva Alan J Silva was born in Brazil and comes from a long line of performers, in fact, he is the sixth generation of circus performers in his family. He started performing at the age of six. He trained and performed in many circus disciplines including Russian bar, clowning, tumbling, and flying trapeze but it wasn’t until he was sixteen that he found his true passion, the aerial silks. Soon after mastering his craft, he was traveling around Brazil performing as the first male artist on aerial silks for circuses and festivals. In 2000, he had the opportunity to audition for his dream circus that only accepted the very best artists to be a part of the company. Two years after his audition, he was called upon to create a character and act for a show that would eventually open on the Las Vegas strip. Since 2003 Alan has called the USA home and proudly received his citizenship in 2017. Whilst working and living in Las Vegas, he met and married his wife and they are now parents of two young children that may follow in his footsteps.Archie Williams 59-year-old Archie is a singer from Baton Rouge, Louisiana, who spent 37 years in prison for a crime he did not commit.On April 21, 1983 at the age of 22, Archie was sentenced to life without parole. In 1995, the Innocence Project got involved in Archie’s case and for over 20 years fought to have DNA run through the FBI Database.On March 14, 2019, this request was finally granted and within hours proved that Archie was innocent. Seven days later on March 21, 2019, the charges were dismissed and he was freed.During his time in prison, Archie turned to music. He was part of the prison choir and formed a band with his fellow inmates. “When I sang people would come to listen” Archie said, “They loved it and wanted to hear me. It brought me joy.”At Archie’s “AGT” audition, he performed, “Don’t Let The Sun Go Down on Me” by Elton John an audition that Simon Cowell said he would never ever forget.BAD Salsa BAD (Bivash Academy of Dance) Salsa, members Sonali Majumder and Sumanth Maroju from India are the winners of “India’s Got Talent” Season 4. Under the direction and mentorship of Bivash Chowdhury, the creator of the brand BAD Salsa, Sonali and Sumanth have participated in more than a thousand national and international events worldwide, receiving recognition and earning several awards in the world of dance. Coming from humble beginnings in small towns in India, Sonali and Sumanth are excited and honored to have made it to the Live Shows of “America’s Got Talent.” With their spine-chilling lifts and fast paced moves fused with the flair of the beautiful culture of India, BAD Salsa promises to show some innovative and unique creations that the world has never seen before!Bello Sisters Loren aged 22, Celine aged 19 and Joline aged 14 are three Italian-German sisters who perform as an acrobatic trio act. They come from an illustrious line of circus performers, their father performed in Cirque du Soleil for 12 years, and their mother was the first woman to walk a high wire with stilts. Training started from a young age, but these three sisters joined forces to create their trio just three years ago. The dream for these sisters is to have their own Bello Family Show in Las Vegas.Brandon Leake Brandon Leake is an award-winning Spoken Word Poet, Artistic Educator and Motivational Speaker from Stockton, California. His creative mixture of art, charisma, and passion tailored to his own unique personal narrative has taken him across the world as a speaker and performer.Performing in locations such as New Zealand, Mexico, Canada, and 36 states around the country for his, “Dark Side Tour” which promoted his first ever published poetry chapbook and his crown jewel “Deficients: A Tale From My Dark Side”. Brandon is also the founder and CEO of Called To Move – CTM an artistry organization with the pursuit of aiding youth development through the art of poetry. This pursuit has led to Brandon leading workshops around the world with several curriculums he has developed himself – in particular, teaching youth in his hometown of Stockton, California.Broken Roots Austin is a popular country musician who plays all over the Chicago-land area. Joey, a popular rock/pop musician who also plays all over the Chicago-land area. In 2019, Austin and Joey were being told repeatedly by venues and people that followed both musicians that they should perform together. They finally met at one of Joey’s shows and realized they actually had many things in common – both worked in law enforcement and cancer had affected their lives in devastating ways. They struggled with their decision to come together musically, both wanting to support each other but feeling like their styles were too different to work together. They eventually decided to break their musical roots and give it a shot by joining forces as a duo on “America’s Got Talent.” Their audition received a standing ovation, four yeses from the judges and they immediately felt the good that can come from courage, sacrifice and compromise in the face of challenge.Cristina Rae Cristina Rae wowed the audience with her phenomenal performance of, “Gimme Shelter” which earned her Heidi Klum’s Golden Buzzer. An arts and biology major, Ms. Rae has been tirelessly pursuing a career in entertainment while working as a body sculptor – though her the role as mother to 4-year-old son Jeremiah gives her the most pride and joy!As a single mother, Cristina has been through her fair share of hardships, which at times, has left her to experience homelessness. Nevertheless, Christina’s brilliance, resilience, and love for her son keeps her heart and eyes set on the ultimate prize, a home to call their own and a successful career as a vocalist!Daneliya Tuleshova Daneliya is a 14-year-old singer from Kazakhstan. She lives with her parents, brother, sister, two hamsters (Vanya, Turbo), dog (Mimi), two cats (Zhasmin, Smo) and her fish. She began singing when she was 10 years old, performing during dinner for her family. In addition to singing, Daneliya enjoys school, reading, cooking pancakes, playing with her best friends and watching American shows on Netflix but her favorite activity is posting dance videos on TikTok. Daneliya has watched “America’s Got Talent” for many years and dreamed of one day being able to come to America and perform on the “AGT” stage. She never thought it would be possible, so this all still feels like a dream. One day, she hopes to be just as big as her inspiration, Beyonce.Kenandi Dodds 15-year-old Kenadi Dodds is a country music singer and songwriter. At the age of nine she went to her first Shania Twain concert and has dreamed of being a country singer ever since. She is inspired everyday by her parents, who are both blind and two younger sisters to pursue this career path.Her father a two-time Paralympian is helping her navigate this path, teaching her the importance of hard work, perseverance and together learning about the music industry and developing her talents. Kenadi is determined to bring love and positivity to the world through her music.Roberta Battaglia Roberta Battaglia (Sofia Vergara’s Season 15 Golden Buzzer) is a dynamic, up-and- coming young vocalist from Toronto, Canada.Born in 2009 into a musical family, Roberta began singing at the age of three alongside her father, Alessandro Battaglia and together the duo have performed at local shows, galas and notable charity events. A second-generation Italian Canadian, Roberta is fluent in both English and Italian and performs a diverse repertoire of music in both languages ranging from ballads to up tempo pop. She has studied singing at a prestigious music academy and performed in competitions and shows including, Idea City presented by television mogul, Moses Znaimer as well as Toronto’s Breakfast Television where her rendition of Lady Gaga’s “Shallow” went viral, resulting in over two million views in two weeks – an outstanding accomplishment for a nine-year-old.Roberta recently launched her own charitable initiative designing bracelets and donating 100% of the sales to Toronto’s world-renowned SickKids Hospital. “It’s about kids helping kids,” explains the philanthropic artist. “I just want to see people smile. I love making everyone happy.”Read original story ‘America’s Got Talent’ Season 15 Finale: And the Winner Is… At TheWrap
In the investing game, it’s not only about what you buy; it’s about when you buy it. One of the most common pieces of advice thrown around the Street, “buy low” is touted as a tried-and-true tactic.Sure, the strategy seems simple. Stock prices naturally fluctuate on the basis of several factors like earnings results and the macro environment, amongst others, with investors trying to time the market and determine when stocks have hit a bottom. In practice, however, executing on this strategy is no easy task.On top of this, given the volatility that has ruled the markets over the last few weeks, how are investors supposed to gauge when a name is flirting with a bottom? That’s where the Wall Street pros come in.These expert stock pickers have identified three compelling tickers whose current share prices land close to their 52-week lows. Noting that each is set to take back off on an upward trajectory, the analysts see an attractive entry point. Using TipRanks’ database, we found out that the analyst consensus has rated all three a Strong Buy, with major upside potential also on tap.Progenity (PROG)Offering clear and actionable genetic results, Progenity specializes in providing testing services. The company started trading on Nasdaq in June and saw its shares tumbling 44% since then. With shares changing hands for $8.11, several members of the Street recommend pulling the trigger before it heats up.Piper Sandler analyst Steven Mah points out that even against the backdrop of COVID-19, PROG managed to deliver with its Q2 2020 performance. “We are encouraged by the recovery in late Q2 2020 with 75,000 accessioned tests (~79,000 in Q1 2020), driven by noninvasive prenatal testing (NIPT) and carrier screening,” the analyst noted. Expounding on this, Mah stated, “Progenity did not provide guidance, but June test volumes of ~28,000 were strong (Q1 2020 monthly average was ~26,000) which we believe showcases the durability of its reproductive tests and the success that Progenity has in co-marketing and attaching carrier screening to the more essential NIPT. Of note, despite the pandemic disruptions, Progenity was able to maintain its leading pre-COVID test turnaround times.”Additionally, health insurer Aetna is temporarily extending coverage of average-risk NIPT until year-end as a result of the pandemic, with the American College of Obstetricians and Gynecologists (ACOG) also expected to endorse average-risk in the future given its clinical utility, in Mah’s opinion.Reflecting another positive, the fourth generation NIPT (single-molecule counting assay) test was able to measure fetal fraction, a key milestone according to Mah, and will continue to be developed into 2021. As the technology could potentially be applied to DNA, RNA, epigenetic markers and proteins for additional clinical applications such as oncology, the analyst is looking forward to the completion of the preeclampsia verification in Q4 2020 and a possible 2H21 launch. “We believe preeclampsia (~2.3 billion serviceable market) is a major differentiator for Progenity, allowing them to cross-sell across the full-continuum of reproductive testing,” the analyst added.If that wasn’t enough, PROG signed its first GI Precision Medicine partnership agreement with a top-20 Pharma company in August. The Oral Biotherapeutic Delivery System (OBDS), an ingestible drug and device combination designed to precisely deliver biologics systemically through a needle-free liquid jet injection into the submucosal tissues of the small intestine, is set to be utilized as part of the collaboration. Mah commented, “We believe Progenity can sign additional Pharma deals and look forward to the newsflow coming out on this front.”To sum it all up, Mah said, “We believe Progenity shares are undervalued given the robust recovery in the core testing business and multiple upcoming growth catalysts.”To this end, Mah rates PROG an Overweight (i.e. Buy) along with a $17 price target. Should his thesis play out, a twelve-month gain of 105% could potentially be in the cards. (To watch Mah’s track record, click here)Are other analysts in agreement? They are. Only Buy ratings, 4, in fact, have been issued in the last three months. Therefore, the message is clear: PROG is a Strong Buy. Given the $13.33 average price target, shares could climb 60% higher in the next year. (See PROG stock analysis on TipRanks)Tactile Systems Technology (TCMD)Developing at-home therapy devices, Tactile Systems Technology wants to provide new treatments for lymphedema, which occurs when the lymphatic system is impaired, disrupting normal transport of fluid within the body, and chronic venous insufficiency. Down 52% year-to-date, its $32.67 share price lands close to its $29.47 52-week low. Thus, with business trends improving, the Street is pounding the table.Writing for Canaccord, analyst Cecilia Furlong acknowledges that the pandemic has hampered the company, with COVID-19 weighing on both volumes and sales. In the second half of March, volumes were down 50% compared to the first half of the month, and TCMD’s patient volumes in April and May remained challenged. That being said, trends started to improve at the end of May.“Going forward, given the vast majority of TCMD’s clinician customers practice in outpatient or office-based settings, we remain positive on TCMD’s ability to demonstrate better insulation against COVID impacts and likely experience a greater bounce-back relative to overall med-tech volume trends, with TCMD further benefitting from its expanding using of technology to remotely engage with clinicians and support patients,” Furlong explained.The analyst added, “Furthermore, recent trends among some providers to prescribe Flexitouch (an advanced intermittent pneumatic compression device to self-manage lymphedema and nonhealing venous leg ulcers) earlier along the therapy process, as a means to reduce in-person contact, could provide upside near term, as well as potentially transition to a longer-term tailwind.”On top of this, Furlong is also optimistic about new CEO Dan Reuvers and the reprioritization of the company’s investment and market development efforts. TCMD will shift focus away from its acquired Airwear product line, with it redirecting investments toward its Flexitouch and Entre (a pneumatic compression device used to assist in the home management of chronic swelling and venous ulcers associated with lymphedema and chronic venous insufficiency) products.“Given significant under-penetration in the lymphedema/phlebolymphedema market targeted by Flexitouch alongside the large patient population with limited treatment options today targeted by the firm’s Head & Neck platform, we view the combination of education and clinical data as key to further developing and penetrating these markets... Going forward, we expect management to continue to compile a broad base of clinical data to support reimbursement and drive broad adoption,” Furlong commented.All of this prompted Furlong to keep a Buy rating and $62 price target on the stock. This target conveys her confidence in TCMD’s ability to soar 90% in the next year. (To watch Furlong’s track record, click here)In general, other analysts are on the same page. With 3 Buy ratings and 1 Hold, the word on the Street is that TCMD is a Strong Buy. The $62.33 average price target brings the upside potential to 91%. (See TCMD stock analysis on TipRanks)uniQure N.V. (QURE)Last but not least we have uniQure, which delivers curative gene therapies that could potentially transform the lives of patients. Even though shares have fallen 44% year-to-date to $40, not much higher than its 52-week low of $36.20, multiple analysts still have high hopes.Representing SVB Leerink, 5-star analyst Joseph Schwartz acknowledges that shares struggled after news broke of its collaboration and licensing agreement with CSL Behring for AMT-061, QURE’s gene therapy for Hemophilia B, he argues the “shareholder base turnover is likely now complete as investors and QURE shift focus to next-in-line AMT-130, its AAV5 gene therapy for Huntington’s Disease (HD).”Schwartz further added, “With the M&A premium now out of the stock, we see the QURE’s current level as an attractive buying opportunity for those investors interested in the company’s up and coming CNS gene therapies, internal manufacturing, and robust intellectual property and knowhow.”Looking more closely at the agreement with CSL Behring, QURE will be tasked with the completion of the pivotal Phase 3 HOPE-B trial as well as the manufacturing process validation and manufacturing supply of AMT-061.According to management, 26-week Factor IX (FIX) data from all 54 patients enrolled in the trial remains on track, and topline data from the pivotal trial is still slated to read out by YE20. It should be mentioned that in a Phase 2b dose-confirmation study, QURE reported 41% FIX activity out to one year. Additionally, Schwartz points out that with HOPE-B progressing as planned, QURE has continued its manufacturing process validation work ahead of the anticipated BLA/MAA submissions in the U.S. and EU in 2021.On top of this, as part of the deal, QURE is eligible to receive more than $2 billion including a $450 million upfront cash payment, $1.6 billion in regulatory and commercial milestones and double-digit royalties ranging up to the low-twenties percentage of net product sales.“With a strengthened cash position, QURE is well funded to rapidly advance CNS assets including AMT-130 (AAV5 gene therapy for Huntington’s Disease (HD)) and AMT-150 (AAV gene therapy for Spinocerebellar Ataxia Type 3/SCA3)...We continue to believe that as QURE’s CNS pipeline assets mature, the company could once again be an attractive partner to larger biopharma companies that have recently acquired many publicly traded gene therapy platforms with substantial manufacturing capabilities,” Schwartz noted.Everything that QURE has going for it convinced Schwartz to reiterate an Outperform (i.e. Buy) rating. Along with the call, he attached a $67 price target, suggesting 68% upside potential from current levels. (To watch Schwartz’s track record, click here)What does the rest of the Street have to say? 9 Buys and 3 Holds have been issued in the last three months, so the consensus rating is a Strong Buy. In addition, the $69.89 average price target indicates 75% upside potential. (See QURE stock analysis on TipRanks)To find good ideas for beaten-down stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
This is so playful and fun From Cosmopolitan